<DOC>
	<DOCNO>NCT00206219</DOCNO>
	<brief_summary>This study compare ZD1839 ( 250mg 500mg ) versus methotrexate head neck cancer term overall survival .</brief_summary>
	<brief_title>Head Neck Phase III Iressa Versus Methotrexate Refractory : Iressa Versus Methotrexate ( IMEX )</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Gefitinib</mesh_term>
	<criteria>Histological confirmation evidence squamous cell carcinoma head neck . Tumors progress primary treatment radiation chemoradiation fail respond least one course standard platinumbased chemotherapy . Tumors progress primary treatment radiation chemoradiation consider unsuitable platinumbased chemotherapy . Carcinomas postnasal space , thyroid , sinus salivary gland tumor . Isolated recurrent disease may amenable local therapy ; e.g. , surgical intervention radiation therapy . Known severe hypersensitivity ZD1839 , Methotrexate excipients product .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2011</verification_date>
	<keyword>Squamous cell carcinoma head neck</keyword>
</DOC>